Used in the treatment of cancers that overexpress EGFR, such as non-small cell lung cancer, colorectal cancer, and head and neck squamous cell carcinoma. It works by binding to the extracellular domain of EGFR, inhibiting ligand-induced receptor activation and downstream signaling pathways involved in cell proliferation, survival, and tumor progression. This monoclonal antibody is primarily employed as a reference standard in preclinical research and assay development for evaluating EGFR-targeted therapies, supporting drug discovery, pharmacokinetic studies, and quality control in biopharmaceutical manufacturing.